Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects
Authors:
- 1 July 2015
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 37 (7) , 1483-1492.e1
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Effects of Hydrochlorothiazide on the Pharmacokinetics, Pharmacodynamics, and Tolerability of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Healthy ParticipantsClinical Therapeutics, 2014
- Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Sodium Glucose Co‐Transporter 2 Inhibitor, in Subjects With Type 2 Diabetes MellitusThe Journal of Clinical Pharmacology, 2013
- Efficacy and Safety of Canagliflozin Treatment in Older Subjects With Type 2 Diabetes Mellitus: A Randomized TrialHospital Practice, 2013
- Changing characteristics of the type 2 diabetes epidemic of China and other Asian countriesJournal of Diabetes Investigation, 2013
- Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exerciseDiabetes, Obesity and Metabolism, 2013
- Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 DiabetesDiabetes Care, 2012
- Canagliflozin, a novel inhibitor of sodium glucose co‐transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjectsDiabetes, Obesity and Metabolism, 2011
- Therapy in the Early Stage: IncretinsDiabetes Care, 2011
- Sodium-Glucose Co-Transport InhibitorsDrugs, 2010
- Diabetes Treatment, Part 2: Oral Agents for Glycemic ManagementClinical Diabetes, 2007